GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Tax Provision

NKGen Biotech (NKGen Biotech) Tax Provision : $-0.01 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Tax Provision?

NKGen Biotech's tax provision for the three months ended in Mar. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01 Mil.


NKGen Biotech Tax Provision Historical Data

The historical data trend for NKGen Biotech's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Tax Provision Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
-0.01 -0.01 -0.01

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Tax Provision Get a 7-Day Free Trial -0.01 - - -0.01 -

NKGen Biotech Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.